In the therapy of hypertension, diabetes, or dyslipidemia or the attempt to prevent solid organ transplant rejection, it is a well recognized strategy to use a number of complementary pharmacologic approaches to address the fundamental goal, whether it is achieving better control of blood pressure (BP), blood sugar, or blood lipids, or long-term allograft survival.

In the assessment of chronic kidney disease–mineral bone disorder (CKD-MBD), serial measurements of serum calcium, phosphorus, and parathyroid hormone (PTH) occur, and attempts are made to bring these levels into the normal range. However, the optimal level of PTH in dialysis patients is not known.

Children who have received solid organ transplants are at high risk of cancer, particularly non-Hodgkin’s lymphoma, according to a study in Pediatrics.

A clinical risk prediction tool based on readily available data performs well in identifying older adults at high risk of death within 6 months after dialysis initiation, reports a study in the American Journal of Kidney Diseases.

For patients who have had acute kidney injury (AKI), the long-term risk of renal progression remains high even if their kidney function ultimately returns to normal, suggests a new study in Kidney International.